Danaher Co. (NYSE:DHR) Holdings Trimmed by Andra AP fonden

Andra AP fonden lowered its holdings in Danaher Co. (NYSE:DHR) by 82.1% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,000 shares of the conglomerate’s stock after selling 4,600 shares during the period. Andra AP fonden’s holdings in Danaher were worth $250,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Cape Investment Advisory Inc. acquired a new stake in Danaher during the 4th quarter worth about $25,000. Tsfg LLC grew its position in Danaher by 733.3% during the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after purchasing an additional 88 shares in the last quarter. CarsonAllaria Wealth Management Ltd. acquired a new position in Danaher in the 2nd quarter valued at approximately $25,000. nVerses Capital LLC purchased a new stake in Danaher in the 2nd quarter worth approximately $25,000. Finally, Redmont Wealth Advisors LLC acquired a new stake in shares of Danaher during the 1st quarter valued at $30,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on DHR shares. StockNews.com lowered Danaher from a “buy” rating to a “hold” rating in a report on Tuesday, June 25th. TD Cowen lifted their price target on Danaher from $290.00 to $310.00 and gave the company a “buy” rating in a report on Wednesday, July 24th. Royal Bank of Canada restated an “outperform” rating and issued a $300.00 price objective on shares of Danaher in a report on Friday, September 6th. Stifel Nicolaus lifted their target price on shares of Danaher from $235.00 to $250.00 and gave the company a “hold” rating in a research note on Wednesday, July 24th. Finally, Jefferies Financial Group assumed coverage on shares of Danaher in a research note on Monday, June 3rd. They set a “buy” rating and a $295.00 price target on the stock. Seven analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat, Danaher currently has an average rating of “Moderate Buy” and an average target price of $278.94.

Danaher Stock Performance

DHR opened at $272.52 on Friday. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. The stock’s 50 day moving average price is $263.85 and its two-hundred day moving average price is $256.33. The firm has a market capitalization of $201.85 billion, a P/E ratio of 46.19, a price-to-earnings-growth ratio of 4.38 and a beta of 0.83. Danaher Co. has a 12-month low of $182.09 and a 12-month high of $281.70.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The business had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.59 billion. During the same quarter in the previous year, the firm posted $2.05 earnings per share. Danaher’s revenue was down 2.9% compared to the same quarter last year. On average, equities analysts forecast that Danaher Co. will post 7.59 earnings per share for the current year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be paid a $0.27 dividend. This represents a $1.08 annualized dividend and a dividend yield of 0.40%. The ex-dividend date is Friday, September 27th. Danaher’s payout ratio is presently 18.31%.

Insider Buying and Selling

In other Danaher news, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares in the company, valued at approximately $1,130,374.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the transaction, the senior vice president now directly owns 4,212 shares in the company, valued at $1,130,374.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Brian W. Ellis sold 9,600 shares of Danaher stock in a transaction on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the sale, the senior vice president now owns 20,230 shares in the company, valued at approximately $5,566,486.80. The disclosure for this sale can be found here. Insiders have sold a total of 39,659 shares of company stock valued at $11,042,433 over the last three months. 11.10% of the stock is owned by corporate insiders.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.